References
- Australian National COVID-19 Clinical Evidence Taskforce, 2020. Australian guidelines for the clinical care of people with COVID-19 Version 16 [online]. Australian National COVID-19 Clinical Evidence Taskforce. Available from: https://app.magicapp.org/#/guideline/4387/section/52237 [Accessed 6 August 2020].
- Bardaji, A., et al., 2015. Troponin elevation in patients without acute coronary syndrome. Revista Española de cardiología, 68 (6), 469–476.
- Biener, M., et al., 2016. Prognostic value of elevated high-sensitivity cardiac troponin T levels in a low risk outpatient population with cardiovascular disease. European heart journal: acute cardiovascular care, 5 (6), 409–418.
- Chen, L., et al., 2020. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular research, 116, 1097–1100.
- Flammer, A.J., et al., 2012. The assessment of endothelial function: from research into clinical practice. Circulation, 126, 753–767.
- Force, A.D.T., et al., 2012. Acute respiratory distress syndrome: the Berlin definition. JAMA, 307, 2526–2533.
- Giannitsis, E., et al., 2000. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation, 102, 211–217.
- Guan, W.J., et al., 2020. Clinical characteristics of Coronavirus disease 2019 in China. New England journal of medicine, 382 (18), 1708–1720.
- Guo, T., et al., 2020. Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). JAMA cardiology, 5 (7), 811–818.
- Han, H., et al., 2020. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clinical chemistry and laboratory medicine, 58 (7), 1116–1120.
- Huang, C., et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. The Lancet, 395 (10223), 497–506.
- Iba, T., et al., 2019. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of thrombosis and haemostasis, 17, 1989–1994.
- Jaffe, A.S., Cleland, J.G.F., and Katus, H.A., 2020. Myocardial injury in severe COVID-19 infection. European heart journal, 41 (22), 2080–2082.
- Januzzi, J.L., 2020. Troponin and BNP use in COVID-19. Washington, DC: American College of Cardiology
- Kwong, J.C., et al., 2018. Acute myocardial infarction after laboratory-confirmed influenza infection. New England journal of medicine, 378 (4), 345–353.
- Lala, A., et al., 2020. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. Journal of the American College of Cardiology, 76 (5), 533–546.
- Lombardi, C.M., et al., 2020. Association of troponin levels with mortality in Italian patients hospitalized with Coronavirus disease 2019: results of a multicenter study. JAMA cardiology, 5 (11), 1274–1280.
- Miesbach, W. and Makris, M., 2020. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clinical and applied thrombosis-hemostasis, 26, 1076029620938149.
- Mucha, S.R., et al., 2020. Coagulopathy in COVID-19: manifestations and management. Cleveland clinic journal of medicine, 87, 461–468.
- Roffi, M., et al., 2016. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European heart journal, 37, 267–315.
- Salbach, C., et al., 2021. Validation of two severity scores as predictors for outcome in Coronavirus Disease 2019 (COVID-19). PLoS one, 16 (2), 16, e0247488.
- Scarpetta S.P.M., Colombo F., and Guanais F., 2020. Beyond containment: health systems responses to COVID-19 in the OECD [online]. Paris, France, Organisation for Economic Co-operation and Development. Available from: https://www.oecd.org/coronavirus/policy-responses/beyond-containment-health-systems-responses-to-covid-19-in-the-oecd-6ab740c0/ [Accessed 8 August 2020].
- Shi, S., et al., 2020. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology, 5 (7), 802–810.
- Siddiqi, H.K. and Mehra, M.R., 2020. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. The journal of heart and lung transplantation, 39, 405–407.
- Solomon, M.D., et al., 2020. The Covid-19 pandemic and the incidence of acute myocardial infarction. New England journal of medicine, 383, 691–693.
- Stoyanov, K.M., et al., 2020. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. European heart journal: acute cardiovascular care, 9 (1), 39–51.
- Tang, N., et al., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18 (4), 844–847.
- Thygesen, K., et al., 2018. Executive group on behalf of the Joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force for the universal definition of myocardial, I., 2018. Fourth universal definition of myocardial infarction. Circulation, 138, e618–e651.
- Tschope, C., et al., 2021. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature reviews cardiology, 18 (3), 169–193.
- Wang, D., et al., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA, 323, 1061–1069.
- Wu, A.H.B., Zhang, Y., and Webber, R., 2020. Extracellular vesicles released in blood of COVID-19 patients: mechanism for detection of cardiac troponin after myocardial injury? Biomarkers, 25 (8), 613–615.
- Zhang, H., et al., 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, 46, 586–590.
- Zhou, F., et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China. The Lancet, 395 (10229), 1054–1062.